文献速递泌尿男性生殖肿瘤

抗氧化酶基因多态性与前列腺癌雄激素剥夺治疗疗效相关并提示氧化应激的影响

Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress.
PubMed 文献 · Ann Oncol · 2017-01-01

研究探讨抗氧化酶基因多态性与雄激素剥夺治疗(ADT)疗效的关系。在转移性前列腺癌中,GSTM3 rs7483 AG/GG allele 与 CRPC 进展风险及全因死亡风险显著降低相关;在非转移性前列腺癌中同样与 CRPC 进展和全因死亡风险降低相关。去势抵抗和恩扎卢胺抵抗细胞中活性氧水平升高伴 GSTM3 表达增强。

要点

  • 转移性前列腺癌中 GSTM3 rs7483 AG/GG 与 CRPC 进展风险降低相关(HR 0.55,95%CI 0.34-0.86,P=0.0086)。
  • 非转移性前列腺癌中 GSTM3 rs7483 AG/GG 与 CRPC 进展风险降低相关(HR 0.35,95%CI 0.10-0.93,P=0.034)。
  • 去势抵抗和恩扎卢胺抵抗细胞中活性氧水平升高伴 GSTM3 表达增强。

核心结论

  • GSTM3 rs7483 多态性可能通过氧化应激途径影响激素治疗耐药,可能成为接受 ADT 前列腺癌患者的有前景的生物标志物。

研究设计与样本

  • 研究检测了抗氧化酶的非同义或启动子区多态性,并分析 104 例转移性和 92 例非转移性前列腺癌患者接受 ADT 后的 CRPC 进展时间和总生存。
  • 此外在去势抵抗和恩扎卢胺抵抗细胞中检测了细胞内活性氧和抗氧化酶表达水平。

主要发现

  • 转移性前列腺癌中,GSTM3 rs7483 AG/GG allele 相比主要 AA 纯合子与 CRPC 进展风险显著降低相关(HR 0.55,95%CI 0.34-0.86,P=0.0086)。
  • 转移性前列腺癌中,CAT rs564250 CT/TT allele 相比 CC 纯合子与全因死亡风险显著降低相关(HR 0.48,95%CI 0.24-0.88,P=0.016)。
  • 多因素分析中,仅 GSTM3 rs7483 与显著进展风险相关(AG/GG 对比 AA;HR 0.45,95%CI 0.25-0.79,P=0.0047),即使经 Bonferroni 校正后仍显著。
  • 非转移性前列腺癌中,GSTM3 rs7483 AG/GG allele 相比 AA allele 与 CRPC 进展风险显著降低相关(HR 0.35,95%CI 0.10-0.93,P=0.034)及全因死亡风险显著降低相关(HR 0.26,95%CI 0.041-0.96,P=0.043)。
  • 去势抵抗和恩扎卢胺抵抗细胞中细胞内活性氧水平升高,伴随 GSTM3 表达增强。

关键数值与推荐

  • 转移性前列腺癌中,GSTM3 rs7483 AG/GG 对比 AA 的 CRPC 进展风险 HR 为 0.55(95%CI 0.34-0.86,P=0.0086)。
  • 转移性前列腺癌中,CAT rs564250 CT/TT 对比 CC 的全因死亡风险 HR 为 0.48(95%CI 0.24-0.88,P=0.016)。
  • 多因素分析中,GSTM3 rs7483 AG/GG 对比 AA 的进展风险 HR 为 0.45(95%CI 0.25-0.79,P=0.0047)。
  • 非转移性前列腺癌中,GSTM3 rs7483 AG/GG 对比 AA 的 CRPC 进展风险 HR 为 0.35(95%CI 0.10-0.93,P=0.034),全因死亡风险 HR 为 0.26(95%CI 0.041-0.96,P=0.043)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oxidative stress mitigated by antioxidant enzymes is thought to be involved in the progression to castration-resistant prostate cancer (CRPC) during androgen-deprivation therapy (ADT). This study investigated the association between genetic variations in antioxidant enzymes and the efficacy of ADT as well as its biological background. PATIENTS AND METHODS: The non-synonymous or promoter-locating polymorphisms of antioxidant enzymes were examined as well as the time to CRPC progression and overall survival in 104 and 92 patients treated with ADT for metastatic and non-metastatic prostate cancer, respectively. In addition, intracellular reactive oxygen species and expression levels of antioxidant enzymes were examined in castration-resistant and enzalutamide-resistant cells. RESULTS: In metastatic prostate cancer, the AG/GG allele in GSTM3 rs7483 and CT/TT allele in CAT rs564250 were associated with a significantly lower risk of progression to CRPC and all-cause death compared with homozygotes of the major AA allele (hazard ratio [HR]; [95% confidence interval (CI)], 0.55 [0.34-0.86], P = 0.0086) and CC allele (HR; [95% CI], 0.48 [0.24-0.88], P = 0.016), respectively. On multivariate analyses, only GSTM3 rs7483 was associated with significant progression risk (AG/GG versus AA; HR; [95% CI], 0.45 [0.25-0.79], P = 0.0047) even after Bonferroni adjustment. In non-metastatic prostate cancer, the AG/GG allele in GSTM3 rs7483 was associated with a significantly lower risk of progression to CRPC (HR; [95% CI], 0.35 [0.10-0.93], P = 0.034) and all-cause death (HR; [95% CI], 0.26 [0.041-0.96], P = 0.043) compared with the AA allele. Intracellular reactive oxygen species levels were increased, accompanied with augmented GSTM3 expression in both castration-resistant and enzalutamide-resistant cells. CONCLUSIONS: Differential activity of antioxidant enzymes caused by the polymorphism in GSTM3 may contribute to resistance to hormonal therapy through oxidative stress. The GSTM3 rs7483 polymorphism may be a promising biomarker for prostate cancer patients treated with ADT.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Shiota M, Fujimoto N, Itsumi M, et al. Gene polymorphisms in antioxidant enzymes correlate with the efficacy of androgen-deprivation therapy for prostate cancer with implications of oxidative stress. Ann Oncol. 2017. PMID: 27993795. doi:10.1093/annonc/mdw646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。